Extra Corporeal Membrane Oxygenation (ECMO) System Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Modality (Veno-Arterial (VA), Veno-Venous (VV), Others), By Application (Respiratory Applications, Cardiac Applications, Extracorporeal Cardiopulmonary Resuscitation (ECPR)), By End-User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region and Competition, 2020-2030F

 Market Overview

Global Extra Corporeal Membrane Oxygenation (ECMO) System Market was valued at USD 571.20 Million in 2024 and is expected to reach USD 782.48 Million in the forecast period with a CAGR of 5.36% through 2030. The Extracorporeal Membrane Oxygenation (ECMO) System Market is experiencing significant expansion due to the growing demand for advanced life-support technologies in critical care settings. ECMO systems play a crucial role in managing patients with severe cardiac and respiratory failure by providing prolonged extracorporeal circulation and oxygenation. Increased awareness among healthcare professionals regarding the effectiveness of ECMO in improving survival rates has contributed to its widespread adoption. The integration of innovative features such as real-time monitoring, compact designs, and automation is further enhancing system performance and usability. Rising cases of cardiovascular diseases, respiratory disorders, and organ failure are driving the need for ECMO, particularly in intensive care units (ICUs) and specialized cardiac centers. Advancements in medical technologies are also improving patient outcomes, making ECMO a preferred intervention in life-threatening conditions.

Advancements in ECMO technology are reshaping the market, leading to the development of portable and user-friendly systems. Increasing investments in research and development have resulted in devices with enhanced efficiency, reduced complications, and improved patient safety. The growing preference for minimally invasive and percutaneous ECMO cannulation techniques has reduced procedural risks and expanded the applicability of ECMO beyond traditional hospital settings. An increasing number of heart and lung transplant procedures also necessitate the use of ECMO for perioperative support, further driving market growth. The integration of artificial intelligence (AI) and data analytics is helping clinicians monitor and optimize ECMO performance, leading to better patient management. Favorable reimbursement policies in developed countries are enhancing patient access to ECMO therapy, while the growing focus on neonatal and pediatric care is expanding the target patient population. Collaborations between healthcare providers and medical device manufacturers are accelerating the adoption of ECMO systems, particularly in emerging markets where critical care infrastructure is rapidly developing.

Despite its benefits, the ECMO System Market faces several challenges that hinder its widespread implementation. High costs associated with ECMO equipment, maintenance, and specialized training limit accessibility, especially in resource-constrained settings. The requirement for highly skilled professionals to operate ECMO machines poses a challenge for healthcare institutions struggling with workforce shortages. Risks of complications such as infections, bleeding, and thrombosis remain concerns that impact the safety profile of ECMO therapy. Stringent regulatory approvals and compliance requirements can delay product commercialization, affecting market expansion. Ethical considerations related to prolonged ECMO support in patients with poor prognosis further complicate decision-making in clinical settings. Limited awareness about ECMO therapy among healthcare providers in certain regions and the need for continuous training to ensure optimal use add to the challenges faced by the market.

Advancements in Medical Technology

Advancements in medical technology have significantly enhanced extracorporeal membrane oxygenation (ECMO) systems, improving their efficacy, safety, and overall utility. These innovations are particularly crucial given the rising prevalence of cardiovascular diseases (CVDs) and respiratory failures, which are leading causes of mortality globally.

In the United States, heart disease remains the leading cause of death, accounting for 702,880 fatalities in 2022, which represents 1 in every 5 deaths. Coronary heart disease (CHD) is the most common type, responsible for 371,506 deaths in the same year. Additionally, about 1 in 20 adults aged 20 and older have CHD. Each year, approximately 805,000 Americans experience a heart attack, with 605,000 being first occurrences and 200,000 happening in individuals who have already had a heart attack. 

The COVID-19 pandemic further underscored the importance of ECMO in managing severe respiratory conditions. A study analyzing data from the 2020 National Inpatient Sample database revealed that among 98,528 mechanically ventilated COVID-19 patients, only 1.8% received ECMO. Notably, in-hospital mortality for these ECMO-treated patients was 49%, compared to 59% for those who did not receive ECMO, suggesting a potential survival benefit. However, ECMO patients had significantly longer hospital stays and were more likely to be discharged to acute care facilities. 

These statistics highlight the critical role of ECMO systems in contemporary healthcare. Continuous technological advancements, such as the development of more efficient and biocompatible oxygenators, improved circuit designs, and system miniaturization, have made ECMO a more viable and accessible option for patients with severe cardiopulmonary conditions. As the burden of heart disease and respiratory failures persists, the ongoing evolution of ECMO technology remains essential in improving patient outcomes and reducing mortality rates associated with these conditions.

Rising Prevalence of Respiratory and Cardiac Disorders

The increasing prevalence of respiratory and cardiac disorders has significantly driven the growth of the Extracorporeal Membrane Oxygenation (ECMO) system market. These conditions have escalated the demand for advanced life support systems like ECMO, which provide critical assistance in severe cases.

ARDS is a life-threatening condition marked by severe respiratory failure. Its prevalence has been influenced by factors such as air pollution, an aging population, and the aftermath of viral outbreaks. In India, a study conducted over a 12-month period in a surgical intensive care unit reported that 7.4% of admitted patients developed ARDS, with a mortality rate of 41.8%. Another study found that among adult autopsies, the prevalence of ARDS was 6.05%, predominantly affecting individuals aged 18–30 years, with a male-to-female ratio of 1.7:1. ECMO serves as a crucial intervention for ARDS patients when conventional ventilation methods fail, highlighting the growing need for such advanced life support systems.

Cardiogenic shock, often resulting from acute myocardial infarction or heart failure, remains a condition with high morbidity and mortality rates. Single-center studies in India have reported mortality rates ranging from 37% to 56% for cardiogenic shock complicating acute coronary syndrome. Furthermore, the incidence of cardiogenic shock in patients with non-ST elevated acute myocardial infarction has been observed at 5%, predominantly in individuals aged 61–70 years. In such critical situations, ECMO acts as a bridge to recovery, maintaining oxygen supply to vital organs until cardiac function is restored.

These statistics underscore the escalating burden of severe respiratory and cardiac conditions in India, emphasizing the vital role of ECMO systems in contemporary critical care settings.

Expanding Applications Beyond Neonatal Care

While ECMO initially gained prominence in neonatal care, its applications have expanded dramatically over the years. This diversification of use has opened up new opportunities in the market.

In the past, ECMO was primarily associated with neonatal and pediatric care. However, technological advancements and clinical research have demonstrated its effectiveness in treating severe respiratory and cardiac failure in adults as well. This expansion to adult patient populations has significantly broadened the ECMO market. ECMO is no longer limited to specific medical conditions. It is now utilized in various scenarios, including post-cardiotomy support, bridge-to-transplant, and as a rescue therapy in cases of refractory cardiac arrest. The ability to adapt ECMO to a wide range of conditions enhances its market potential and underscores its versatility.

Growing Awareness and Training Initiatives

Increased awareness and comprehensive training programs are pivotal in driving ECMO adoption among healthcare professionals.

Medical institutions and organizations have recognized the need to educate healthcare personnel about ECMO technology. Training programs, workshops, and certification courses have become more widespread, ensuring that medical staff are proficient in ECMO procedures. This not only boosts the confidence of healthcare providers but also encourages the integration of ECMO in clinical practice. Growing public awareness about ECMO's life-saving potential has prompted more individuals to seek it as a treatment option for their loved ones. The rise in patient and family advocacy has led to increased discussions with healthcare providers regarding the suitability of ECMO in critical cases, further fostering its adoption.

The ECMO system market is witnessing substantial growth due to a combination of factors, including technological advancements, the rising incidence of respiratory and cardiac disorders, expanding applications beyond neonatal care, and the proliferation of awareness and training initiatives. These drivers collectively underscore the transformative role of ECMO in modern healthcare and its increasing significance in saving lives across diverse patient populations.

Download Free Sample Report

Key Market Challenges

High Costs and Resource Intensity

ECMO therapy is a highly specialized and resource-intensive medical intervention. The equipment itself is expensive, and the overall cost of ECMO treatment includes not only the machine but also the required disposables, personnel, and infrastructure. Running an ECMO program demands a skilled team of healthcare professionals, including perfusionists and specially trained nurses, as well as dedicated facilities with the necessary technology and expertise.

Financial Burden: The high upfront costs associated with establishing and maintaining an ECMO program can be a substantial financial burden for healthcare institutions, particularly smaller hospitals and clinics. Due to the resource-intensive nature of ECMO, it may not be readily available in all healthcare settings, limiting access for patients in remote areas or regions with fewer healthcare resources. The cost barrier can exacerbate healthcare disparities, as not all patients may have equal access to ECMO treatment, potentially leading to unequal outcomes based on socioeconomic factors.

Complications and Risks

While ECMO is a life-saving intervention, it is not without risks and complications. Patients undergoing ECMO therapy are at risk of various complications, including bleeding, infections, and clot formation. Managing these complications requires vigilant monitoring and expertise, adding to the complexity of ECMO care.

The risk of complications can lead to increased morbidity among ECMO patients, which can be particularly concerning when ECMO is used as a last-resort therapy for critically ill individuals. Healthcare professionals must undergo specialized training to manage ECMO-related complications effectively. Ensuring a skilled workforce can be a challenge for healthcare institutions. Careful patient selection is essential to minimize risks, but determining who is a suitable candidate for ECMO can be a complex decision that requires thorough evaluation and expertise.

Ethical and Legal Considerations

The use of ECMO raises a host of ethical and legal considerations. These include decisions surrounding when to initiate or withdraw ECMO therapy, the allocation of resources, and the delicate balance between preserving life and ensuring a patient's quality of life. Ethical dilemmas can arise when determining the futility of ECMO in cases where recovery is unlikely.

Deciding when to withdraw ECMO support in cases of irreversible brain injury or terminal illness can be emotionally challenging for both healthcare providers and families. ECMO resources are finite, and allocation decisions must be made, potentially leading to ethical dilemmas about who receives treatment and who does not. ECMO carries legal implications, and healthcare providers must navigate complex legal frameworks when making treatment decisions and obtaining informed consent.

Key Market Trends

Technological Advancements and Miniaturization

One prominent trend in the global ECMO System Market is the continuous advancement of technology and the development of more compact, portable ECMO systems. This trend aims to make ECMO therapy more accessible and versatile.

Miniaturized ECMO Machines: Manufacturers are working on creating smaller, more portable ECMO machines that are easier to transport and set up. This makes ECMO treatment feasible in a wider range of healthcare settings, including ambulances and remote clinics. ECMO systems are increasingly being integrated with advanced monitoring devices and artificial intelligence algorithms. This integration allows for real-time monitoring of patient vitals, helping healthcare providers make informed decisions and detect complications earlier. Some ECMO systems now offer wireless connectivity, enabling healthcare teams to monitor patients remotely. This feature is especially valuable for critical care patients who require continuous monitoring even during inter-hospital transfers.

Increased Use of ECMO in Respiratory Pandemics

The COVID-19 pandemic has accelerated the adoption of ECMO therapy, especially in cases of severe respiratory distress. This trend has highlighted the importance of ECMO in managing critical respiratory conditions.

ECMO has been used as a last-resort therapy for COVID-19 patients with severe acute respiratory distress syndrome (ARDS). It serves as a bridge to recovery when mechanical ventilation alone is insufficient. During the pandemic, there was a surge in demand for ECMO equipment and expertise, leading to the expansion of ECMO programs in many healthcare institutions. The increased use of ECMO during the pandemic has spurred research efforts to better understand its efficacy and outcomes in COVID-19 patients. This has resulted in a growing body of data and evidence supporting the use of ECMO in respiratory pandemics.

Personalized Medicine and ECMO

Advances in genomics and personalized medicine are influencing the ECMO field, allowing for more tailored treatment approaches and better patient outcomes.

Some healthcare institutions are using genomic profiling to identify patients who may be more likely to benefit from ECMO treatment. This personalized approach helps optimize patient selection and improve the chances of success. Understanding how a patient's genetics affect their response to medications used during ECMO therapy can lead to more effective drug dosing and fewer adverse reactions. Personalized medicine also involves precise monitoring of patients on ECMO. This may include adjusting ECMO settings based on individual patient responses to treatment.

Segmental Insights

Modality Insights

Based on the Modality, the veno-arterial (VA) emerged as the dominant player in the global market for Extra Corporeal Membrane Oxygenation (ECMO) System in 2024. The dominance of the veno-arterial (VA) modality in the Global ECMO (Extracorporeal Membrane Oxygenation) System Market can be attributed to several factors, including its versatility and widespread applicability. The The VA ECMO modality provides comprehensive support by assisting not only with severe respiratory failure but also with cardiac dysfunction. This versatility makes it suitable for a broader range of patients, including those experiencing cardiogenic shock or cardiac arrest. In contrast, the veno-venous (VV) ECMO modality primarily addresses respiratory failure alone. VA ECMO plays a crucial role in cardiac surgery, particularly during complex procedures such as heart transplants and coronary artery bypass grafting (CABG). It offers circulatory support during these surgeries, allowing surgeons to perform intricate procedures with greater confidence. This close association with cardiac surgery contributes significantly to the prominence of the VA modality. Cardiogenic shock is a life-threatening condition characterized by severe heart dysfunction, leading to inadequate blood circulation. VA ECMO provides immediate circulatory support by diverting blood from the venous system, oxygenating it, and returning it to the arterial system. This rapid intervention can be a lifesaving measure in cases of cardiogenic shock. VA ECMO is sometimes used as a rescue therapy in cases of refractory cardiac arrest when standard resuscitative measures are ineffective. It can temporarily take over the pumping function of the heart, providing vital oxygenation and circulation until the underlying cause of the arrest is addressed.

Additionally, VA ECMO has demonstrated its life-saving potential in various clinical settings. Its ability to rapidly stabilize patients with acute heart or lung failure and maintain vital organ perfusion makes it indispensable in critical care scenarios. The integration of VA ECMO into cardiac surgery procedures has solidified its position in the market. Surgeons rely on ECMO support during complex cardiac surgeries, ensuring patient safety and surgical success. The continual research and innovation in ECMO technology, particularly in the VA modality, have led to improvements in safety and efficacy. This ongoing development reinforces its position as the primary choice for ECMO support. These factors are expected to drive the growth of this segment.

Application Insights

Based on the Application, the respiratory application emerged as the dominant player in the global market for Extra Corporeal Membrane Oxygenation (ECMO) System in 2024. The dominance of the respiratory application in the Global ECMO (Extracorporeal Membrane Oxygenation) System Market can be attributed to several reasons, including the prevalence of severe respiratory conditions, technological advancements, and the expanding range of respiratory applications. Respiratory conditions are highly prevalent worldwide. Factors such as air pollution, smoking, aging populations, and the aftermath of respiratory infections (like COVID-19) contribute to a growing incidence of severe respiratory illnesses. This increased prevalence drives the demand for ECMO systems tailored to respiratory applications. The COVID-19 pandemic has had a significant impact on the ECMO market. Severe cases of COVID-19 often result in ARDS, where patients struggle to breathe due to damaged lung tissue. ECMO emerged as a crucial therapy in such cases, reinforcing its role in respiratory applications. Respiratory ECMO applications are vital in neonatal and pediatric care. Premature infants with underdeveloped lungs or congenital respiratory conditions often require ECMO support to survive. This segment of the ECMO market remains essential, contributing to the overall dominance of respiratory applications. These factors collectively contribute to the growth of this segment.

Download Free Sample Report

Regional Insights

North America emerged as the dominant region in the global Extra Corporeal Membrane Oxygenation (ECMO) System market in 2024, holding the largest market share in terms of value. The United States has a well-developed healthcare infrastructure, including numerous advanced hospitals and clinics that can offer ECMO services. This infrastructure allows for the widespread availability of ECMO therapy. North America faces a high burden of critical medical conditions, such as acute respiratory distress syndrome (ARDS) and cardiac emergencies. The prevalence of these conditions drives the demand for ECMO systems, especially in large metropolitan areas. The region is at the forefront of medical technology and research. Continuous advancements in ECMO technology, including miniaturization and improved circuit designs, are developed and adopted more rapidly here. North America is home to numerous research institutions and clinical trial centers. This environment fosters innovation in ECMO therapy, leading to improved outcomes and expanding the range of ECMO applications. Significant healthcare investments and insurance coverage in North America contribute to higher healthcare expenditure, which includes the adoption of advanced medical technologies like ECMO.

The Asia-Pacific market is poised to be the fastest-growing market, offering lucrative growth opportunities for Extra Corporeal Membrane Oxygenation (ECMO) System players during the forecast period. Factors such as Many countries in the Asia-Pacific region are increasing their healthcare budgets and investments in medical infrastructure. This includes the expansion of intensive care units (ICUs) equipped with ECMO capabilities. Awareness of ECMO therapy's effectiveness is on the rise in Asia-Pacific. Healthcare professionals and patients are becoming more familiar with its benefits, leading to increased adoption. The region's growing middle-class population is seeking better healthcare options. As a result, the demand for advanced medical treatments like ECMO is increasing. Several countries in Asia are experiencing demographic shifts, with a rapidly aging population. This demographic trend correlates with an increased incidence of critical medical conditions that may require ECMO support. Emerging economies in Asia, such as China and India, are making substantial strides in healthcare infrastructure development. These countries have a large population base and are expected to witness significant ECMO market growth.

Recent Developments

• In January 2025, InflaRx N.V. announced that the European Commission (EC) granted marketing authorization under exceptional circumstances for GOHIBIC (vilobelimab). This approval allows its use in adult patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) receiving systemic corticosteroids and invasive mechanical ventilation (IMV), with or without extracorporeal membrane oxygenation (ECMO). GOHIBIC is the first and only approved treatment for SARS-CoV-2-induced ARDS in the European Union.
• In October 2024, Hyperfine, Inc. announced the publication of a study highlighting the use of its FDA-cleared portable MR brain imaging system, the Swoop system, for patients on extracorporeal membrane oxygenation (ECMO) support. Conducted by investigators at Johns Hopkins Hospital and the University of Texas-Houston, the study, published in Circulation, assessed the safety of bedside ultra-low-field MRI for ECMO patients in cardiac ICUs and examined the occurrence of acute brain injury (ABI). The findings reinforce the potential of portable MRI in critical care settings, improving accessibility to brain imaging for high-risk patients.
• In September 2024, Inspira Technologies OXY B.H.N. Ltd. participated in the 34th Annual Extracorporeal Life Support Organization (ELSO) Conference in Detroit, Michigan. The company showcased its latest advancements and future innovations in oxygenation and blood circulation technologies aimed at enhancing respiratory and critical care treatments. Inspira Technologies presented groundbreaking solutions designed to improve patient outcomes, reduce reliance on mechanical ventilation, and optimize extracorporeal life support. This participation highlighted the company’s commitment to revolutionizing critical care through cutting-edge medical technologies.
• In September 2024, Medtronic launched VitalFlow, a configurable ECMO (extracorporeal membrane oxygenation) system designed for long-term cardiopulmonary support. The system, featuring a large touchscreen for real-time data monitoring, incorporates Medtronic’s Nautilus ECMO oxygenator for enhanced performance. Medtronic acquired VitalFlow from MC3 Cardiopulmonary in March 2024, concluding an eight-year partnership that introduced seven ECMO products. This launch reinforces Medtronic’s commitment to advancing cardiopulmonary care and follows recent acquisitions, including a Viant Medical contract manufacturing site and the Penditure Left Atrial Appendage Exclusion System.
• In July 2024, Inspira Technologies OXY B.H.N. Ltd. received approval from the Israeli Ministry of Health (AMAR) for its INSPIRA ART100, an Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass system. This approval marks a key milestone in the company’s efforts to advance business development and market entry for its innovative medical technologies.

Key Market Players

• LivaNova (Alung Technologies Inc.)
• Eurosets
• Getinge AB
• Medtronic PLC
• Microport Scientific Corporation
• Nipro Medical Corporation
• Terumo Medical Corporation
• Abbott Laboratories
• Fresenius Medical Care Company

 Report Scope:

In this report, the Global Extra Corporeal Membrane Oxygenation (ECMO) System Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Extra Corporeal Membrane Oxygenation (ECMO) System Market, By Modality:

o   Veno-Arterial (VA)

o   Veno-Venous (VV)

o   Others

• Extra Corporeal Membrane Oxygenation (ECMO) System Market, By Application:

o   Respiratory Applications

o   Cardiac Applications

o   Extracorporeal Cardiopulmonary Resuscitation (ECPR)

• Extra Corporeal Membrane Oxygenation (ECMO) System Market, By End-User:

o   Hospitals & Clinics

o   Ambulatory Care Centers

o   Others

• Extra Corporeal Membrane Oxygenation (ECMO) System Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Extra Corporeal Membrane Oxygenation (ECMO) System Market.

Available Customizations:

Global Extra Corporeal Membrane Oxygenation (ECMO) System market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Extra Corporeal Membrane Oxygenation (ECMO) System Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com